Abstract:Introduction: Post-operative pancreatic fistula (POPF) remains the lethal complication after pancreaticoduodenectomy, and the objective of the study is evaluating the preventive effect of somatostatin on POPF in intermediate risk patients. Methods: A multi-center, randomized, controlled study was conducted in six high-volume pancreas centers in China between June 2018 and April 2019. Patients undergoing pancreaticoduodenectomy with intermediate risk of POPF were enrolled. Patients were randomly assigned to somatostatin group (intravenous somatostatin of 250μg/h for 120 hours) and control group. The primary endpoint was clinically relevant POPF (CR-POPF) (according to 2016 International Study Group on Pancreatic Fistula criteria). This trial was registered with Clinical Trial (NCT03349424). Results: 205 patients were enrolled and 99 in somatostatin group and 100 in control group were included for final analysis. The rate of CR-POPF in somatostatin group decreased significantly (13% vs 25%, p=0.032), both in open and laparoscopic pancreaticoduodenectomy. But the rates of overall POPF (65% vs 69%, p=0.51) and biochemical leak (52% vs 44%, p=0.29) were not significantly different. Medical costs (¥115069 vs ¥115803, p=0.92) and other complications: biliary fistula (6% vs 6%, p=0.99), abdominal infection (19% vs 18%, p=0.83), chylous fistula (5% vs 4%, p=0.75), late postoperative hemorrhage (7% vs 12%, p=0.24) had no significant difference. However, the somatostatin group had higher rate of delayed gastric emptying (33% vs 21%, p=0.0504). Conclusion: In patients with intermediate risk of POPF after pancreaticoduodenectomy, prophylactic use of somatostatin can reduce the CR-POPF, but seems to increase the rate of delayed gastric emptying.OP04-19The baseline characteristics of study participantsOverall (n=199)somatostatin group (n=99)control group (n=100)Age, mean (SD), yrs58.857.92 (11.4)59.18 (10.7)Male sex123(62%)57 (57%)66 (66%)BMI, mean (SD) (kg/m2)22.922.58 (3.2)23.26 (3.2)Hypertension inmedical history56(28%)56(28%)32 (32%)Diabetes mellitus in medical history33(17%)16 (16%)17 (17%)Chronic pancreatitis in medical history2(1%)2 (2%)0(0%)Acute pancreatitis in medical history5(3%)0(0%)5 (5%) Open table in a new tab

Prophylactic somatostatin can reduce incidence of post-ERCP pancreatitis: multicenter randomized controlled trial.

Somatostatin administration prior to ERCP is effective in reducing the risk of post-ERCP pancreatitis in high-risk patients.

Effect of Somatostatin on Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis and Hyperamylasemia: A Systematic Review and Meta-Analysis.

Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials

Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate

Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis

Clinical Study of Prophylactic Effect of Proton Pump Inhibitor Combined with Somatostatin and Gabexate on Post-ERCP Pancreatitis and Hyperamylasemia

Effect of Octreotide Administration in the Prophylaxis of Post-Ercp Pancreatitis and Hyperamylasemia: A Multicenter, Placebo-Controlled, Randomized Clinical Trial

Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial

A randomised, multicentre trial of somatostatin to prevent clinically relevant postoperative pancreatic fistula in intermediate-risk patients after pancreaticoduodenectomy

Randomized, Placebo-Controlled Study of the Efficacy of Preoperative Somatostatin Administration in the Prevention of Postoperative Complications Following Pancreaticoduodenectomy.

Somatostatin Prevents Clinically Relevant Pancreatic Fistula in Intermediate Risk Patients after Pancreaticoduodenectomy (SPEED): A Multi-center, Randomized, Controlled Study

Glyceryl Trinitrate For Prevention Of Post-Ercp Pancreatitis And Improve The Rate Of Cannulation: A Meta-Analysis Of Prospective, Randomized, Controlled Trials

APPLICATION OF SOMATOSTATIN FOR THE PREVENTION OF COMPLICATIONS FOLLOWING PANCREATODUODENECTOMY

Effect of Octreotide on prophylaxis of post ERCP pancreatitis and hyperamylasemia:a multicenter,randomized clinical trial

Clinical research on the prophylactic effects of pancreatic duct stenting combined with non-storied anti-inflammatory drug on post endoscopic retrograde cholangiopancreatography pancreatitis in difficult bile duct cannulation

The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis

Pancreatic surgical complications--the case for prophylaxis

Pancreatic duct stent preventing post endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients

Systematic Review on Somatostatin Combined with Omeprazole for Treating Acute Pancreatitis

Pharmacological prophylaxis versus pancreatic duct stenting plus pharmacological prophylaxis for prevention of post-ERCP pancreatitis in high risk patients: a randomized trial